Skip to main content
SpringerLink
Log in

Is There a Role for Adjuvant High-Dose Interferon-α-2b in the Management of Melanoma?

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The knowledge that melanoma is susceptible to attack by the host’s immune system has resulted in the testing of a variety of immunotherapies. Interferon-α-2b, which has several anti-tumour mechanisms including an antiproliferative effect, an anti-angiogenesis effect, the enhancement of natural-killer cell activity and the upregulation of tumour antigen presentation, has shown tremendous potential. Early trials using low-dose and intermediate-dose regimens demonstrated no benefit to survival. However, the Eastern Cooperative Oncology Group trial EST 1684, showed that a high-dose regimen involving an induction phase of intravenous interferon-α-2b 20 MU/m2 5 days a week for 4 weeks, followed by a maintenance phase of subcutaneous 10 MU/m2 3 days a week for the remainder of a year, led to significant improvements in both disease-free and overall survival compared with observation. On the basis of these results, the US FDA approved high-dose interferon-α-2b for the post-surgical adjuvant therapy of high-risk melanoma. Unfortunately, the results of subsequent trials involving high-dose interferon-α-2b have not been as clear, and its role in the adjuvant treatment of melanoma remains controversial. Concerns remain regarding the design and interpretation of the clinical trials, the cost and toxicity of treatment, and the appropriate selection of patients who should be treated. This article reviews the existing data and attempt to address the arguments for and against a role for adjuvant high-dose interferon-α-2b in the management of melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16): 3635–48

    PubMed  CAS  Google Scholar 

  2. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489–99

    PubMed  CAS  Google Scholar 

  3. Frank SJ, Meyers M. Interferon as adjuvant therapy for high risk melanoma. Melanoma Lett 1995; 13: 1–4

    Google Scholar 

  4. Legha SS. Current therapy for maligant melanoma. Semin Oncol 1989; 16: 34–44

    PubMed  CAS  Google Scholar 

  5. Steiner A, Wolf CH, Pehamberger H. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 1987; 113: 459–65

    Article  PubMed  CAS  Google Scholar 

  6. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14(1): 7–17

    PubMed  CAS  Google Scholar 

  7. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20(7): 1818–25

    Article  PubMed  CAS  Google Scholar 

  8. Kokoschka EM, Trautinger F, Knobler RM, et al. Long-term adjuvant therapy of high risk malignant melanoma with interferon a2b. J Invest Dermatol 1990; 95 Suppl.: S193–7

    Article  Google Scholar 

  9. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme [letter]. Lancet 1994; 343: 913–4

    Article  PubMed  CAS  Google Scholar 

  10. Cascinelli N. Evaluation of efficacy of adjuvant rIFNα 2a in melanoma patients with regional node metastases [abstract]. Proc Am Soc Clin Oncol 1994; 14: 410

    Google Scholar 

  11. Rusciani L, Petraglia S, Alotto M, et al. Postsurgical adjuvant therapy for melanoma: evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer 1997; 79(12): 2354–60

    Article  PubMed  CAS  Google Scholar 

  12. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alpha-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13: 2776–83

    PubMed  CAS  Google Scholar 

  13. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C 9190. J Clin Oncol 2000; 18(12): 2444–58

    PubMed  CAS  Google Scholar 

  14. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C 509801. J Clin Oncol 2001; 19(9): 2370–80

    PubMed  CAS  Google Scholar 

  15. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12(5): 1036–44

    PubMed  CAS  Google Scholar 

  16. Santinami M, Maurichi A, Patuzzo R, et al. Impact of clinical trials on the treatment of melanoma. Surg Oncol Clin N Am 2001; 10(4): 935–47

    PubMed  CAS  Google Scholar 

  17. Kirkwood JM, Manola J, Ibrahim J, et al. Pooled analysis of four ECOG/Intergroup trials of high-dose interferon alpha-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma [abstract]. Proc Am Soc Clin Oncol 2001; 20: 350a

    Google Scholar 

  18. Punt CJA, Eggermont AM. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies. Ann Oncol 2001; 12: 1633–66

    Google Scholar 

  19. Hillner BE, Kirkwood JM, Atkins MB, et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997; 15(6): 2351–8

    PubMed  CAS  Google Scholar 

  20. Hillner BE. Cost effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk cutaneous melanoma. Eur J Cancer 1998; 34 Suppl. 3: S18–21

    Article  PubMed  Google Scholar 

  21. Gonzalez-Larriba JL, Serrano S, Alvarez-Mon M, et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer 2000; 36(18): 2344–52

    Article  PubMed  CAS  Google Scholar 

  22. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14(10): 2666–73

    PubMed  CAS  Google Scholar 

  23. Dickler MN, Coit DG, Myers ML. Adjuvant therapy of malignant melanoma. Surg Oncol Clin N Am 1997; 6(4): 793–812

    PubMed  CAS  Google Scholar 

  24. Thome SD, Loprinzi CL, Heidebrandt MP. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanoma. Mayo Clin Proc 2002; 77: 913–7

    PubMed  Google Scholar 

  25. Wheatley K, Hancock B, Gore M. Interferon-alpha as adjuvant therapy for melanoma: a meta-analysis of the randomised trials [abstract]. Proc Am Soc Clin Oncol 2001; 20: 349a

    Google Scholar 

  26. Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E 2696. J Clin Oncol 2001; 19(5): 1430–6

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. Both Dr Sabel and Dr Sondak serve on the Schering-Oncology speakers bureau.

Author information

Authors and Affiliations

  1. 3304 Cancer Center, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, USA

    Michael S. Sabel & Vernon K. Sondak

Authors
  1. Michael S. Sabel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vernon K. Sondak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael S. Sabel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sabel, M.S., Sondak, V.K. Is There a Role for Adjuvant High-Dose Interferon-α-2b in the Management of Melanoma?. Drugs 63, 1053–1058 (2003). https://doi.org/10.2165/00003495-200363110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363110-00001

Keywords

Search

Navigation